Results of the votes of the Combined Shareholders’ Meeting of April 16, 2021

Results of the votes of the Combined Shareholders’ Meeting of April 16, 2021




Results of the votes of the Combined Shareholders’ Meeting of April 16, 2021

Daix (France), April 19, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need,  today announced the results of the votes of its Combined Shareholders’ Meeting on April 16, 2021. 

The Combined Shareholders’ Meeting was held under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva, at the Company’s registered office, 50, rue de Dijon – 21121 Daix, France, virtually, without the physical presence of the shareholders and other persons entitled to attend, in accordance with the derogatory measures relating to the adaptation of the rules of meeting and deliberation of shareholders’ meetings taken by the French authorities because of the COVID-19 pandemic.

All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 24th resolution which would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company.

Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders’ Meeting approved, without modification, the compensation policy for corporate officers as presented in the 2020 Universal Registration Document (Part 3.5.1, pages 141 and seq.).

Information on the results of the votes is detailed below:

  • Total number of shares composing the share capital: 38 630 261
  • Total number of shares with voting rights: 38 585 566
 

 

                            

Ordinary part Extraordinary part
Shareholders Shares Votes Shareholders Shares Votes
  Shareholders present 0 0 0 0 0 0
  Proxy to third parties 0 0 0 0 0 0
  Proxy to the Chairman 221 2 652 173 2 673 283 221 2 652 173 2 673 283
  Mail votes 113 27 197 719 38 630 397 113 27 197 719 38 630 397
  TOTAL 334 29 849 892 41 303 680 334 29 849 892 41 303 680
  Quorum 77.36% 77.36%
               


Resolutions State of adoption Number of represented shares Proportion of represented share capital
(%)
Total number of votes cast

 

For Against Abstention
  Number of votes in % of votes cast Number of votes in % of votes cast Number of votes in % of the total voting rights
Resolution 1 – OGM Adopted 29 849 892 77.27% 41 303 315 41 303 183 >99.99% 132 0.00% 365 0.00%
Resolution 2 – OGM Adopted 29 849 892 77.27% 41 303 358 41 303 183 >99.99% 175 0.00% 322 0.00%
Resolution 3 – OGM Adopted 29 849 892 77.27% 41 303 352 41 303 190 >99.99% 162 0.00% 328 0.00%
Resolution 4 – OGM Adopted 29 849 892 77.27% 41 303 175 41 303 043 >99.99% 132 0.00% 505 0.00%
Resolution 5 – OGM Adopted 29 849 892 77.27% 41 300 747 39 439 449 95.49% 1 861 298 4.51% 2 933 0.01%
Resolution 6 – OGM Adopted 29 849 892 77.27% 41 300 730 39 439 383 95.49% 1 861 347 4.51% 2 950 0.01%
Resolution 7 – OGM Adopted 29 849 892 77.27% 41 300 788 41 103 691 99.52% 197 097 0.48% 2 892 0.01%
Resolution 8 – OGM Adopted 29 849 892 77.27% 41 301 840 40 440 278 97.91% 861 562 2.09% 1 840 0.00%
Resolution 9 – OGM Adopted 29 849 892 77.27% 41 301 840 40 440 324 97.91% 861 516 2.09% 1 840 0.00%
Resolution 10 – OGM Adopted 29 849 892 77.27% 41 301 990 41 292 738 99.98% 9 252 0.02% 1 690 0.00%
Resolution 11 – OGM Adopted 29 849 892 77.27% 41 302 851 41 302 429 >99.99% 422 0.00% 829 0.00%
Resolution 12 – OGM Adopted 29 849 892 77.27% 41 302 820 41 302 530 >99.99% 290 0.00% 860 0.00%
Resolution 13 – OGM Adopted 29 849 892 77.27% 41 302 783 41 302 543 >99.99% 240 0.00% 897 0.00%
Resolution 14 – OGM Adopted 29 849 892 77.27% 41 303 308 39 435 344 95.48% 1 867 964 4.52% 372 0.00%
Resolution 15 – EGM Adopted 29 849 892 77.27% 41 302 548 41 105 591 99.52% 196 957 0.48% 1 132 0.00%
Resolution 16 – EGM Adopted 29 849 892 77.27% 41 302 502 39 440 822 95.49% 1 861 680 4.51% 1 178 0.00%
Resolution 17 – EGM Adopted 29 849 892 77.27% 41 302 552 39 437 788 95.49% 1 864 764 4.51% 1 128 0.00%
Resolution 18 – EGM Adopted 29 849 892 77.27% 41 249 716 39 384 922 95.48% 1 864 794 4.52% 53 964 0.11%
Resolution 19 – EGM Adopted 29 849 892 77.27% 41 249 666 39 385 456 95.48% 1 864 210 4.52% 54 014 0.11%
Resolution 20 – EGM Adopted 29 849 892 77.27% 41 249 686 39 485 599 95.72% 1 764 087 4.28% 53 994 0.11%
Resolution 21 – EGM Adopted 29 849 892 77.27% 41 249 644 39 386 420 95.48% 1 863 224 4.52% 54 036 0.11%
Resolution 22 – EGM Adopted 29 849 892 77.27% 41 302 480 39 440 265 95.49% 1 862 215 4.51% 1 200 0.00%
Resolution 23 – EGM Adopted 29 849 892 77.27% 41 302 584 39 432 702 95.47% 1 869 882 4.53% 1 096 0.00%
Resolution 24 – EGM Rejected 29 849 892 77.27% 41 298 555 14 132 290 34.22% 27 166 265 65.78% 5 125 0.01%
Resolution 25 – EGM Adopted 29 849 892 77.27% 41 298 575 41 297 126 >99.99% 1 449 0.00% 5 105 0.01%
Resolution 26 – EGM Adopted 29 849 892 77.27% 41 297 529 39 436 321 95.49% 1 861 208 4.51% 6 151 0.01%
Resolution 27 – EGM Adopted 29 849 892 77.27% 41 301 251 39 439 037 95.49% 1 862 214 4.51% 2 429 0.00%
Resolution 28 – EGM Adopted 29 849 892 77.27% 41 298 590 39 435 399 95.49% 1 863 191 4.51% 5 090 0.01%
Resolution 29 – OGM Adopted 29 849 892 77.27% 41 302 445 41 301 162 >99.99% 1 283 0.00% 1 235 0.00%


About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com

Contacts

Inventiva
Frédéric Cren
Chairman & CEO
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick Group
Yannick Tetzlaff / Tristan Roquet Montegon / 
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513 1284 


Attachment